 |
|
|
|
July 1999 Cover
|
|
The Nordic VAC-04 Study Group has found no apparent clinical benefit of immunization with recombinant HIV-1 gp160 (rgp160). The study, published in a recent issue of Lancet, noted significantly fewer deaths in the vaccine group at six months, as compared to the placebo group; but at the end of the study, approximately the same number of patients had developed AIDS or died. However, investigators posit that because the vaccine was well-received and achieved a modest increase in CD4 counts, it may be effective in restoring functional immunity when used in combination with highly active antiretroviral therapy.
Editor's Note: from Reuters
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
